Clinical trials: Fat Sensitivity
Asthma
Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics
Asthmatics who are significantly overweight tend to have more severe symptoms, more flare ups, and are more likely to have poorly-controlled asthma when compared to other asthmatics.
- Trial name
- GLITZ Asthma (NCT00634036)
- Testing
- pioglitazone
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Fernando Holguin
Obesity
Prevention of Obesity in Women Via Estradiol Regulation
The purpose of this study is to evaluate potential mechanisms by which estradiol deficiency accelerates fat gain and abdominal fat accumulation in women.
- Trial name
- POWER (NCT00687739)
- Testing
- leuprolide acetate, Estradiol Transdermal, progressive resistance exercise training
- Where
- United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Obesity
Effect of Time-restricted Eating on Catecholamine-sensitivity of Adipose Tissue in Obese Adults
In a randomized controlled trial, the investigators intend to measure the health impact of time-restricted eating (TRE) in obese patients (body mass index (BMI) ≥ 30 kg/m2), who habitually eat for more than 14 hours every day.
- Trial name
- NCT04916730
- Testing
- Standard of Care, Time Restricted Eating
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- University of California, San Diego
Advanced Malignant Neoplasm
Fat Emulsion in Preventing Hypersensitivity Reactions in Patients With Cancer Receiving Carboplatin or Oxaliplatin
This randomized pilot trial studies how well fat emulsion works in preventing hypersensitivity reactions in patients with cancer receiving carboplatin or oxaliplatin.
- Trial name
- NCT03122886
- Testing
- Fat Emulsion
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mayo Clinic
Obesity, Fatty Liver, Nonalcoholic
Effects of Pitavastatin on Insulin Sensitivity and Liver Fat
HMG co-A reductase inhibitors, commonly called statins, are an effective treatment for dyslipidemia and atherosclerotic heart disease with proven mortality benefit.
- Trial name
- NCT02290106
- Testing
- pitavastatin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Obesity, Impaired Glucose Tolerance
Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth
The purpose of the study is to determine whether treatment of children and adolescents with Impaired Glucose Tolerance (IGT) with rosiglitazone will lead to improvements in insulin sensitivity and glucose tolerance.
- Conditions
- Obesity, Impaired Glucose Tolerance, Type 2 Diabetes Mellitus
- Trial name
- NCT00413335
- Testing
- Rosiglitazone
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Yale University
Prediabetic State, Non-alcoholic Fatty Liver Disease
ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD
A Phase 2a, randomized, double-blind, placebo-controlled, multi-center study of cenicriviroc (CVC) to be conducted in approximately 50 adult obese subjects [body mass index (BMI) ≥ 30 kg/m^2] with prediabetes or type 2 diabetes…
- Conditions
- Prediabetic State, Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
- Trial name
- NCT02330549
- Testing
- Cenicriviroc 150 mg
- Where
- 3 sites in United States, Puerto Rico
- Volunteers
- 45 people
- Sponsor
- Tobira Therapeutics, Inc.
Asthma, Obesity
Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics (Glitz Asthma)
Asthmatics who are significantly overweight tend to have more severe symptoms, more flare ups, and are more likely to have poorly-controlled asthma when compared to other asthmatics.
- Trial name
- GLITZ (NCT00787644)
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Vermont
Insulin Sensitivity/Resistance, Obesity
Insulin-sensitive Obesity: Lessons From Longitudinal Data
People who are overweight and/or obese are at risk of insulin resistance and type 2 diabetes. However, research has shown that some overweight and/or obese individuals remain insulin-sensitive and metabolically healthy despite…
- Trial name
- ISOS (NCT02017210)
- Where
- Australia
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Garvan Institute of Medical Research